1. Evaluating the diagnostic performance of Liaison® chemiluminescence assay as screening tool for detection of acute Epstein-Barr infection: A comparative study.
- Author
-
Tortosa-Carreres J, Lloret-Sos C, Sahuquillo-Arce JM, Suárez-Urquiza P, Prat-Fornells J, Molina-Moreno JM, Alba-Redondo A, Martínez-Triguero ML, Aguado-Codina C, Laiz-Marro B, and López-Hontangas JL
- Subjects
- Humans, Child, Young Adult, Luminescence, Sensitivity and Specificity, Antibodies, Viral, Immunoglobulin M, Antigens, Viral, Herpesvirus 4, Human, Epstein-Barr Virus Infections
- Abstract
The present investigation assessed the Liaison® diagnostic performance in detecting Epstein-Barr (EBV) IgM-VCA in a large patient cohort, considering age and symptomatology. VIDAS® were employed as a benchmark for acute EBV infection. The study also probed other coexisting conditions and potential cross-reactivity for error sources. A total of 1311 samples were analyzed, with notable associations found only among paediatric (kappa=0.75) and young adult (kappa=0.58) populations with compatible symptoms. ROC analysis revealed varying optimal cutoff values based on age and symptom categorizations. Logistic regression models identified age and patients from Oncology or Infectious Disease as significant factors for false positives. Potential interferences emerged with RF, ANCA, cytomegalovirus-IgM and VHS-IgM. Notably, Liaison® couldn´t distinguish EBV patients from Oncology, Haemathology or Internal Medicine. This study provides valuable insights, such as implementing ageand symptom-specific thresholds or reviewing test requests, for optimizing EBV serology in microbiology laboratories, leading to faster and more reliable responses., Competing Interests: Declaration of Competing Interest The authors declare that they have no conflicts of interest related to this research. There are no financial, personal, or professional relationships that could potentially bias or influence the interpretation of the results presented in this study., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF